Previous close | 374.00 |
Open | 374.00 |
Bid | 387.00 x 0 |
Ask | 388.20 x 0 |
Day's range | 371.60 - 388.00 |
52-week range | 255.00 - 554.00 |
Volume | |
Avg. volume | 66,929 |
Market cap | 6.735B |
Beta (5Y monthly) | 1.30 |
PE ratio (TTM) | 45.26 |
EPS (TTM) | 8.55 |
Earnings date | 11 Sept 2024 |
Forward dividend & yield | 6.00 (1.60%) |
Ex-dividend date | 13 Oct 2023 |
1y target est | 437.50 |
4 July 2024 Major shareholder announcement – BlackRock, Inc. ANNOUNCEMENT NO. 271 Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock Investment Management (UK) Limited on 3 July 2024, increased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to above 10%, and that the holding thus exceeds the 10 per cent limit in section 38 of
ANNOUNCEMENT NO. 270 2 July 2024 Preliminary revenue figures for the 2023/24 financial year In the fourth quarter of the 2023/24 financial year, ChemoMetec's revenue was DKK 109.2 million, corresponding to a growth of 13.5% from the year-earlier period. The revenue for the 2023/24 financial year was DKK 407.4 million against DKK 442.3 million the previous year, corresponding to a decrease of 7.9%. The revenue in 2023/24 is thus in line with the latest disclosed guidance for the revenue of DKK 40
ANNOUNCEMENT NO. 269 Appointment of new CFO The board of ChemoMetec has appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The